Emtricitabine/tenofovir

Emtricitabine/tenofovir is used both to treat and to prevent HIV/AIDS. HIV prevention The Centers for Disease Control and Prevention (CDC) recommends the use of emtricitabine/tenofovir for pre-exposure prophylaxis (PrEP) for uninfected, HIV-1 negative individuals that may be at risk for HIV-1 infection. A Cochrane systematic review found a 51% relative risk reduction of contracting HIV with both tenofovir alone and the tenofovir/emtricitabine combination. A JAMA systematic review found a similar relative risk reduction of 54% on average and greater reduction with greater adherence. It was approved for PrEP against HIV infection in the United States in 2012. The CDC recommends PrEP be considered for the following high-risk groups: • Individuals in an ongoing sexual relationship with an HIV-positive partner • Gay or bisexual men who either have had anal sex without a condom or have been diagnosed with an STD in the past six months • Heterosexual men or women who do not regularly use condoms during sex with partners of unknown HIV status who are substantial risk • Injection of drugs in the last six months with sharing of equipment • Serodiscordant heterosexual and homosexual partners, where one partner is HIV-positive and the other HIV-negative The consideration of utilizing emtricitabine/tenofovir as a reduction strategy involves discussion with a health professional who can help the patient navigate the benefits and risks. Patients are advised to discuss any history of bone issues, kidney issues, or hepatitis B infection with their healthcare provider. Effectiveness of PrEP for prevention of infection is reliant on an individual's ability to take the medication consistently. Emtricitabine/tenofovir is also used for HIV post-exposure prophylaxis. People who start taking emtricitabine/tenofovir see HIV reduction benefits up to 72 hours after starting, but the medicine must be taken for thirty days after a high-risk sexual event to ensure HIV transmission levels are optimally reduced. Emtricitabine/tenofovir as PrEP should not be used for individuals who are positive for HIV-1. Hepatitis B Both emtricitabine and tenofovir are indicated for the treatment of hepatitis B, with the added benefit that they can target HIV for those with co-infection. Emtricitabine/tenofovir may also be considered for some antiviral resistant hepatitis B infections. Pregnancy and breastfeeding In the United States, it is recommended that all pregnant HIV-infected women start antiretroviral therapy (ART) as early in pregnancy as possible to reduce the risk of transmission. ART generally does not increase risk of birth defects with exception of dolutegravir, which is not recommended during first trimester of pregnancy only due to potential risk of neural tube defects. Emtricitabine/tenofovir is secreted in breast milk. In developed countries, HIV-infected mothers are generally recommended to not breastfeed due to slight risk of mother-to-children HIV transmission. In developing countries, where avoiding breastfeeding may not be an option, the World Health Organization recommends a triple drug regimen of tenofovir, efavirenz, and either lamivudine or emtricitabine. ==Side effects==

Emtricitabine/tenofovir is generally well tolerated. Some of its side effects include: Weight changes have, however, been linked to the medication. ==Drug interactions==

Other drugs with adverse reactions include dabigatran etexilate, lamivudine, and vincristine. Dabigatran etexilate used with p-glycoprotein inducers requires monitoring of decreased levels and effects of dabigatran. Lamivudine may increase the adverse or toxic effect of emtricitabine. Vincristine used with P-glycoprotein/ABCB1 inducers can decrease the serum concentration of vincristine. ==Society and culture==

The patent for the drug combination is owned by Gilead Sciences in some regions. The European patent EP0915894B1 expired in July 2018, but Gilead Sciences wished the patent to be extended. Four rival labsTeva, Accord Healthcare, Lupin and Mylanhad sought to have that overturned in the courts in Britain, and the High Court of Justice invalidated Gilead's patent. Gilead appealed and the UK referred the case to the European Court of Justice, which refused to extend the patent. An Irish court rejected an injunction request to prevent the launch of generic Emtricitabine/tenofovir prior to the resolution of the case. Despite the expiration of the Gilead Sciences patent, as of 2021, there are still widespread challenges to the availability and uptake of generic PrEP throughout Europe. In 2019, Gilead Sciences challenged the validity of patents granted to the United States after 2015 for using the drug combination for HIV PrEP and post-exposure prophylaxis (PEP). In July 2024, The Biden administration appealed the jury finding that ruled in favor of Gilead Sciences verdict that the U.S. government's patents are invalid. In the United States, most healthcare plans are required to cover PrEP without any copay or other cost sharing. This is due to a United States Preventive Services Task Force recommendation that gave PrEP a grade A rating. Under the Affordable Care Act, this recommendation requires all non-grandfathered private health plans to cover PrEP without cost sharing. In the United Kingdom, PrEP is widely available to all at-risk groups following the Department for Health and Social Care's decision to make it available across England in 2020. Wales, Scotland, and Northern Ireland made it available in 2017 and 2018. ==References==